OKYO Pharma Limited Share Price London S.E.
Equities
OKYO
GG00BMFG5F62
Pharmaceuticals
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 51.35M 4.09B |
---|---|---|---|---|---|
Net income 2024 * | -11M -876M | Net income 2025 * | -15M -1.19B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.86
x | P/E ratio 2025 * |
-4.07
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.63% |
Managers | Title | Age | Since |
---|---|---|---|
Gary Jacob
CEO | Chief Executive Officer | 77 | 06/01/21 |
Keeren Shah
DFI | Director of Finance/CFO | 47 | 31/07/20 |
William Clementi
COO | Chief Operating Officer | - | 31/08/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Brancaccio
BRD | Director/Board Member | 76 | 09/06/20 |
Willy Simon
BRD | Director/Board Member | 72 | 31/05/15 |
Gabriele Cerrone
CHM | Chairman | 52 | 06/01/21 |
1st Jan change | Capi. | |
---|---|---|
-3.79% | 87.06B | |
+2.76% | 40.25B | |
-17.49% | 31.09B | |
+54.18% | 24.74B | |
-13.13% | 15.91B | |
-9.12% | 11.96B | |
-15.45% | 11.92B | |
-42.56% | 11.61B | |
+5.84% | 8.73B |